Cytovance, Selexys partner up for sickle cell antibody
Cytovance Biologics Inc. has partnered with Selexys Pharmaceuticals Corp. to produce the SelG1 monoclonal antibody for a clinical study that will advance the product through phase II clinical studies.
SelG1, for patients with sickle cell disease, will be produced at Cytovance’s 44,000-square-foot production facility in Oklahoma City. This isn’t the first time the two organizations have partnered up. In 2010, Selexys and Cytovance collaborated to manufacture the Anti-PSGL-1 therapeutic agent, a monoclonal antibody developed for treatment of inflammation associated with Crohn’s disease.